OR WAIT null SECS
© 2022 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2022 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
November 29, 2022
The decision to move forward in Phase III development stems from the threat of resistance to current malaria treatment growth.
November 17, 2022
CellVax Therapeutics has selected Theragent, a new CDMO, to manufacture clinical trial material for a new Phase II prostate cancer immunotherapy drug candidate.
September 20, 2022
Regulatory officials are addressing challenges in ensuring that clinical data can be relied on in making regulatory decisions.
April 20, 2022
New guidance from FDA and legislation from Congress promote clinical trial diversity.
April 01, 2022
Under the two-year task order, ATCC will continue to support the DCEG MEAS program in receiving, processing, storing, analyzing, and distributing clinical specimens from different cancer types.
March 25, 2022
Huma has acquired AstraZeneca’s digital health platform, and AstraZeneca has become a shareholder of Huma in a partnership to accelerate digital-first patient care.
March 02, 2022
Optimizing the use of partners for clinical trials depends on selecting the right contractor.
Capacity concerns and regulatory compliance considerations will drive the decision about outsourcing the manufacture of clinical trial materials.
February 22, 2022
FDA officials and their scientific advisors have come down hard on clinical development programs that rely on study results from a single foreign country, instead of from multi-regional trials following harmonized R&D standards.
November 15, 2021
Under the expanded agreement with Agios, Centogene will provide global clinical trial support for thalassemia and sickle cell diseases.